Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13255-13268

  Zucha, Muhammad Ary ^a,b   Wu, Alexander T H ^a,c   Lee, Wei Hwa ^d   Wang, Liang Shun ^e   Lin, Wan Wan ^a   Yuan, Chiou Chung ^f   Yeh, Chi Tai ^d,e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b GADJAH MADA UNIVERSITY   (Indonesia)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f Taipei Medical Univers Shuang Ho Hospital   (Taiwan)

Author keywords

Bruton's tyrosine kinase (Btk); Cancer stem cell (CSC); Cisplatin; Ibrutinib; Ovarian cancer; Spheroids

Indexed keywords

BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; CELL MARKER; CISPLATIN; IBRUTINIB; JANUS KINASE 2; STAT3 PROTEIN; TRANSCRIPTION FACTOR SOX2; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTINEOPLASTIC AGENT; JAK2 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; STAT3 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM LIKE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; GENE INDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR SPHEROID; UPREGULATION; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; METABOLISM; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; YOUNG ADULT;

ADULT; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JANUS KINASE 2; MIDDLE AGED; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; STAT3 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84931092005     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. The New England journal of medicine. 2009;361:170-177.
2. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012;62:10-29.
3. Bast RC, Jr., Hennessy B and Mills GB. The biology of ovarian cancer: new opportunities for translation. Nature reviews Cancer. 2009;9:415-428.
4. Whittemore AS. Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecologic oncology. 1994;55:S15-19.
5. Zhan Q, Wang C and Ngai S. Ovarian cancer stem cells: a new target for cancer therapy. BioMed research international. 2013;2013:916819.
6. Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA and Neamati N. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:16348-16353.
7. Chen J, Wang J, Zhang Y, Chen D, Yang C, Kai C, Wang X, Shi F and Dou J. Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture. Journal of bioscience and bioengineering. 2014;118:214-222.
8. Ahmed N, Abubaker K, Findlay J and Quinn M. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. Journal of cellular biochemistry. 2013;114:21-34.
9. McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH, Daggett J, Jr., Cullen K, Kantoff E, Hasselbatt K, Berkowitz J, Muto MG, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:E2939-2948.
10. Menendez JA, Corominas-Faja B, Cuyas E and Alarcon T. Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions. Oncoscience. 2014;1:803-806.
11. Qiu Y and Kung HJ. Signaling network of the Btk family kinases. Oncogene. 2000;19:5651-5661.
12. Ma S and Rosen ST. Signal transduction inhibitors in chronic lymphocytic leukemia. Current opinion in oncology. 2011;23:601-608.
13. Rushworth SA, Murray MY, Zaitseva L, Bowles KM and MacEwan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood. 2014;123:1229-1238.
14. Singhal E, Kumar P and Sen P. A novel role for Bruton's tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells. The Journal of biological chemistry. 2011;286:32054-32063.
15. Foon KA, Takeshita K and Zinzani PL. Novel therapies for aggressive B-cell lymphoma. Advances in hematology. 2012;2012:302570.
16. Lassmann S, Schuster I, Walch A, Gobel H, Jutting U, Makowiec F, Hopt U and Werner M. STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3- inducible targets linked to cell survival and proliferation. Journal of clinical pathology. 2007;60:173-179.
17. Dave B, Landis MD, Tweardy DJ, Chang JC, Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D and Lewis MT. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PloS one. 2012;7:e30207.
18. Mezzanzanica D, Balladore E, Turatti F, Luison E, Alberti P, Bagnoli M, Figini M, Mazzoni A, Raspagliesi F, Oggionni M, Pilotti S and Canevari S. CD95-mediated apoptosis is impaired at receptor level by cellular FLICEinhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004;10:5202-5214.
19. Lee CM, Su YH, Huynh TT, Lee WH, Chiou JF, Lin YK, Hsiao M, Wu CH, Lin YF, Wu AT and Yeh CT. BlueBerry Isolate, Pterostilbene, Functions as a Potential Anticancer Stem Cell Agent in Suppressing Irradiation-Mediated Enrichment of Hepatoma Stem Cells. Evidence-based complementary and alternative medicine: eCAM. 2013;2013:258425.
20. Liu S, Liu C, Min X, Ji Y, Wang N, Liu D, Cai J and Li K. Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis. PloS one. 2013;8(11):e81050.
21. Buchholz S, Keller G, Schally AV, Halmos G, Hohla F, Heinrich E, Koester F, Baker B and Engel JB. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:10403-10407.
22. Rosano L, Spinella F, Di Castro V, Dedhar S, Nicotra MR, Natali PG and Bagnato A. Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Molecular cancer therapeutics. 2006;5:833-842.
23. Buick RN, Pullano R and Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer research. 1985;45:3668-3676.
24. Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, Manderson EN, Provencher D and Mes-Masson AM. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene. 2001;20:6617-6626.
25. Smith JA, Ngo H, Martin MC and Wolf JK. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecologic oncology. 2005;98:141-145.
26. Freeburg EM, Goyeneche AA, Seidel EE and Telleria CM. Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity. Cancer cell international. 2009;9:4.
27. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS and Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell stem cell. 2007;1:555-567.
28. Tan SL, Liao C, Lucas MC, Stevenson C and DeMartino JA. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Pharmacology & therapeutics. 2013;138:294-309.
29. Baba Y, Hashimoto S, Matsushita M, Watanabe D, Kishimoto T, Kurosaki T and Tsukada S. BLNK mediates Syk-dependent Btk activation. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:2582-2586.
30. Yan H and Sun Y. Evaluation of the mechanism of epithelial-mesenchymal transition in human ovarian cancer stem cells transfected with a WW domain-containing oxidoreductase gene. Oncology letters. 2014;8:426-430.
31. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH, Small JM and Gynecologic Oncology G. Secondary surgical cytoreduction for advanced ovarian carcinoma. The New England journal of medicine. 2004;351:2489-2497.
32. Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Fruh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O and Lee SM. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012;30:1692-1698.
33. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature reviews Cancer. 2007;7(8):573-584.
34. Kelland LR. New platinum antitumor complexes. Critical reviews in oncology/hematology. 1993;15:191-219.
35. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y and Noguchi S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009;15:4234-4241.
36. Liu SY and Zheng PS. High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer. Oncotarget. 2013;4:2462-2475.
37. Itamochi H, Kigawa J and Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer science. 2008;99:653-658.
38. Deleyrolle LP, Ericksson G, Morrison BJ, Lopez JA, Burrage K, Burrage P, Vescovi A, Rietze RL and Reynolds BA. Determination of somatic and cancer stem cell selfrenewing symmetric division rate using sphere assays. PloS one. 2011;6:e15844.
39. Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, Li J, Zhang Y, Chen L, Qian H, Wu M and Yin Z. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC gastroenterology. 2011;11:71.
40. Shield K, Ackland ML, Ahmed N and Rice GE. Multicellular spheroids in ovarian cancer metastases:Biology and pathology. Gynecologic oncology. 2009;113:143-148.
41. Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB, Morrison CD and Odunsi K. Ovarian cancer spheroid cells with stem celllike properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PloS one. 2014;9(1):e84941.
42. Liu KC, Yo YT, Huang RL, Wang YC, Liao YP, Huang TS, Chao TK, Lin CK, Weng SJ, Ma KH, Chang CC, Yu MH and Lai HC. Ovarian cancer stem-like cells show induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor. Oncotarget. 2013;4:2366-2382.
43. Janumyan YM, Sansam CG, Chattopadhyay A, Cheng N, Soucie EL, Penn LZ, Andrews D, Knudson CM and Yang E. Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. The EMBO journal. 2003;22:5459-5470.
44. McDermott J and Jimeno A. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. Drugs of today. 2014;50:291-300.